Legacy Financial Advisors Inc. lifted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 16.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,596 shares of the medical research company's stock after buying an additional 948 shares during the quarter. Legacy Financial Advisors Inc.'s holdings in Amgen were worth $1,719,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Blossom Wealth Management lifted its holdings in shares of Amgen by 3.5% during the 4th quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company's stock valued at $284,000 after purchasing an additional 37 shares in the last quarter. Zullo Investment Group Inc. boosted its holdings in shares of Amgen by 2.8% in the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock valued at $356,000 after buying an additional 37 shares during the period. Trillium Asset Management LLC increased its position in shares of Amgen by 4.2% during the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock worth $237,000 after acquiring an additional 37 shares in the last quarter. Evermay Wealth Management LLC increased its position in shares of Amgen by 1.5% during the fourth quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company's stock worth $691,000 after acquiring an additional 38 shares in the last quarter. Finally, Great Lakes Retirement Inc. raised its holdings in shares of Amgen by 0.4% during the fourth quarter. Great Lakes Retirement Inc. now owns 10,220 shares of the medical research company's stock worth $2,664,000 after acquiring an additional 38 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on AMGN shares. Piper Sandler increased their target price on Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Piper Sandler Companies reaffirmed an "overweight" rating and set a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. UBS Group lifted their price objective on shares of Amgen from $315.00 to $319.00 and gave the company a "neutral" rating in a report on Monday. Royal Bank of Canada restated an "outperform" rating and set a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Finally, StockNews.com upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, April 9th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Amgen has a consensus rating of "Moderate Buy" and a consensus price target of $314.91.
Read Our Latest Stock Analysis on AMGN
Amgen Stock Performance
Shares of NASDAQ AMGN traded up $0.76 during trading on Tuesday, reaching $294.68. 1,221,575 shares of the stock traded hands, compared to its average volume of 2,772,608. The stock has a market capitalization of $158.43 billion, a P/E ratio of 39.03, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The company has a 50-day moving average of $304.05 and a 200-day moving average of $294.91.
Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.
Amgen Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.23%. Amgen's payout ratio is currently 126.09%.
Insider Buying and Selling at Amgen
In related news, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the completion of the transaction, the executive vice president now owns 44,186 shares of the company's stock, valued at approximately $13,025,590.94. This trade represents a 16.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock valued at $20,644,335 over the last 90 days. 0.69% of the stock is currently owned by corporate insiders.
About Amgen
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Recommended Stories
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
